CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE
    • Publication Information:
      Publication: <2003->: Athens : D.A. Spandidos
      Original Publication: [Athens, Greece] : National Hellenic Research Foundation, 1994-
    • Subject Terms:
      Biomarkers, Tumor/*genetics ; Breast Neoplasms/*genetics ; Cell Movement/*genetics ; Chemokines, CC/*genetics; Animals ; Apoptosis/genetics ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Cell Adhesion/genetics ; Cell Proliferation/genetics ; Chemokines, CC/antagonists & inhibitors ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; MCF-7 Cells ; Matrix Metalloproteinase 2/genetics ; Matrix Metalloproteinase 9/genetics ; Mice ; Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors ; Mitogen-Activated Protein Kinase Kinases/genetics ; Neoplasm Metastasis/genetics ; Signal Transduction/genetics ; Xenograft Model Antitumor Assays
    • Abstract:
      Breast cancer is one of the most commonly diagnosed cancers worldwide and the second leading cause of cancer-related deaths among females. CCL28 (mucosa-associated epithelial chemokine, MEC), a CC subfamily chemokine, has been well studied in the process of inflammation, and recently increasing evidence indicates that CCL28 is related to tumor progression. However, little is known concerning its function in breast cancer. In the present study, we generated a CCL28-overexpressing breast cancer cell line MDA-MB-231HM/CCL28 from parental MDA-MB‑231HM cells. We found that overexpression of CCL28 promoted cell proliferation and tumor formation, and also enhanced migration, invasion and metastasis both in vitro and in vivo. Mechanistic studies revealed that CCL28 mediated intracellular activation of the mitogen-activated protein kinase (MAPK) signaling pathway to promote breast cancer cell proliferation and metastasis by upregulating anti-apoptotic protein Bcl-2 and suppressing cell adhesion protein β-catenin. However, overexpression of CCL28 did not influence the expression of metastasis‑related protein matrix metalloproteinase MMP2 and MMP9 and VEGF. Tissue sample analysis from animal models also indicated that overexpression of CCL28 was associated with enhanced pERK expression and reduced β-catenin expression in breast carcinomas. Thus, our results show for the first time that CCL28 contributes to breast cancer progression through the ERK/MAPK‑mediated anti-apoptotic and metastatic signaling pathway. Antagonists of CCL28 and the MAPK signaling pathway may be used synergistically to treat breast cancer patients.
    • References:
      Clin Cancer Res. 2009 May 1;15(9):2962-70. (PMID: 19383822)
      Res Vet Sci. 2010 Jun;88(3):422-6. (PMID: 20022349)
      Exp Dermatol. 2006 Feb;15(2):95-100. (PMID: 16433680)
      J Immunol. 2003 Feb 1;170(3):1452-61. (PMID: 12538707)
      Science. 2011 Mar 25;331(6024):1559-64. (PMID: 21436443)
      Blood. 2013 May 9;121(19):3838-42, S1-15. (PMID: 23509159)
      J Exp Med. 2003 Nov 3;198(9):1337-47. (PMID: 14581607)
      Cytokine. 2012 Jul;59(1):94-9. (PMID: 22503614)
      J Immunol. 2000 Sep 15;165(6):2943-9. (PMID: 10975800)
      Cancer Res. 2012 Jun 1;72(11):2768-79. (PMID: 22472119)
      Cancer Res. 2011 Mar 15;71(6):2056-65. (PMID: 21406396)
      Nature. 2011 Jun 08;475(7355):222-5. (PMID: 21654748)
      Breast Cancer Res Treat. 2012 Feb;131(3):837-48. (PMID: 21479551)
      J Breast Cancer. 2016 Sep;19(3):252-260. (PMID: 27721874)
      J Appl Physiol (1985). 2010 Feb;108(2):343-8. (PMID: 19959769)
      Nature. 2009 Jul 9;460(7252):225-30. (PMID: 19525930)
      Mol Hum Reprod. 2013 Oct;19(10):676-86. (PMID: 23737337)
      J Biol Chem. 2012 Oct 19;287(43):36593-608. (PMID: 22927430)
      Anticancer Res. 2004 Nov-Dec;24(6):4243-6. (PMID: 15736479)
      Int J Oncol. 2006 Feb;28(2):315-9. (PMID: 16391784)
      Carcinogenesis. 2007 Jan;28(1):174-82. (PMID: 16829690)
      CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. (PMID: 22237781)
      PLoS One. 2013;8(1):e53068. (PMID: 23349697)
      Anticancer Res. 2005 Nov-Dec;25(6C):4707-12. (PMID: 16334164)
      Am J Pathol. 2004 Mar;164(3):997-1006. (PMID: 14982853)
      J Exp Med. 2004 Sep 20;200(6):805-9. (PMID: 15381732)
      Cytokine Growth Factor Rev. 2010 Feb;21(1):27-39. (PMID: 20004131)
      Mol Cancer Res. 2008 Aug;6(8):1276-88. (PMID: 18708360)
      Med Oncol. 2015 Jul;32(7):208. (PMID: 26099171)
      Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1062-9. (PMID: 15246961)
      Int J Oncol. 2001 May;18(5):939-44. (PMID: 11295038)
      PLoS One. 2014 Mar 11;9(3):e91245. (PMID: 24618835)
      Clin Cancer Res. 2010 Aug 1;16(15):3875-86. (PMID: 20505188)
      Nature. 2011 Jul 13;475(7355):226-30. (PMID: 21753853)
      Cancer Cell. 2011 Apr 12;19(4):541-55. (PMID: 21481794)
      Cell Immunol. 2005 Dec;238(2):87-96. (PMID: 16581045)
      J Biol Chem. 2000 Jul 21;275(29):22313-23. (PMID: 10781587)
      Oncogene. 2006 Nov 16;25(54):7201-11. (PMID: 16785997)
      J Leukoc Biol. 2006 Apr;79(4):639-51. (PMID: 16478915)
      Onco Targets Ther. 2014 Jun 13;7:1033-42. (PMID: 24966685)
      Exp Ther Med. 2012 Jul;4(1):65-69. (PMID: 23060924)
      J Immunol. 2006 Jul 1;177(1):593-603. (PMID: 16785557)
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (CCL28 protein, human)
      0 (Chemokines, CC)
      EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
      EC 3.4.24.24 (MMP2 protein, human)
      EC 3.4.24.24 (Matrix Metalloproteinase 2)
      EC 3.4.24.35 (MMP9 protein, human)
      EC 3.4.24.35 (Matrix Metalloproteinase 9)
    • Publication Date:
      Date Created: 20170718 Date Completed: 20180417 Latest Revision: 20220408
    • Publication Date:
      20221213
    • Accession Number:
      PMC5549038
    • Accession Number:
      10.3892/or.2017.5798
    • Accession Number:
      28713975